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Abstract
Background: Ovarian cancer is the second most common cancer of the female genital tract in the United
Kingdom (UK), accounting for 6% of female deaths due to cancer. This cancer is associated with poor survival and
there is a need for new treatments in addition to existing chemotherapy to improve survival. Potassium (K+)
channels have been shown to be overexpressed in various cancers where they appear to play a role in cell
proliferation and progression.
Objectives: To determine the expression of the potassium channels Eag and HERG in ovarian cancer tissue and to
assess their role in cell proliferation.
Methods: The expression of Eag and HERG potassium channels was examined in an ovarian cancer tissue
microarray. Their role in cell proliferation was investigated by blocking voltage-gated potassium channels in an
ovarian cancer cell line (SK-OV-3).
Results: We show for the first time that high expression of Eag channels in ovarian cancer patients is significantly
associated with poor survival (P = 0.016) unlike HERG channel expression where there was no correlation with
survival. There was also a significant association of Eag staining with high tumour grade (P = 0.014) and presence
of residual disease (P = 0.011). Proliferation of SK-OV-3 cells was significantly (P < 0.001) inhibited after treatment
with voltage gated K+ channel blockers.
Conclusion: This novel finding demonstrates a role for Eag as a prognostic marker for survival in patients with
ovarian cancer.
Introduction
Ovarian cancer is the second most common malignancy
of the female genital tract in the UK. Cancer statistics
from 2007 reveal that 4,317 UK women died from ovar-
ian cancer, accounting for around 6% of all female
deaths from cancer [1]. Despite advances in chemother-
apy, ovarian cancer mortality rates in the UK since the
early 1970 s, have remained stable at ~10-12 per
100,000 women. This is in part due to the asymptomatic
nature of the disease with most women presenting at a
late stage [1]. Current treatment with platinum based
chemotherapy results in clinical remission in 75% of
patients but the median progression free survival is only
16 to 21 months [2]. Thus, there is a clear need for the
development of novel therapies to improve conventional
treatments and identify new prognostic markers for
survival.
Ion channels are pore-forming proteins that help
establish and control voltage gradients across the plasma
membranes of all living cells by allowing the flow of
ions down their electrochemical gradient [3]. Voltage
gated potassium (K+) channels have recently generated
great interest due to their involvement in cell prolifera-
tion in various cancers [4]. Moreover, K+ channel block-
ers have been shown to inhibit proliferation of the
ovarian cancer cell line A2780 [5], identifying voltage-
gated K+ channels as potential therapeutic candidates
for the treatment of cancer.
Four main K+ channel subtypes (Kv1.3, K2p9.1, Eag and
HERG) are found to be overexpressed in a number of
tumour types [4]. K+ channels have been suggested to be
involved in cancer through the action on membrane poten-
tial and regulation of cell volume [6]. Hyperpolarisation of
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the cancer cells mediated by K+ channels not only leads to
increased Ca2+ influx [7] a well known factor for regulation
of cell proliferation but also maintains the driving force for
Na+ dependent nutrient transport and influencing intracel-
lular pH [6]. K+ channels have also been shown to affect
cell proliferation due to their regulation of intracellular
concentration of solute involved in DNA synthesis or acti-
vating a cell cycle regulating protein through the effect on
cell volume, in fact rat glioma cells show optimal prolifera-
tion in a small range of cell volume [8].
Eag (Ether-a-go-go, Kv10.1) was first isolated from the
fruitfly Drosophilia melanogaster as the leg shaking phe-
notype induced under ether anesthesia [9]. Eag has a
restricted distribution limited to the central nervous sys-
tem [10] and expressed transiently in myoblasts [11].
Chinese Hamster Ovary (CHO) cells transfected with
the Eag gene show increased proliferation, growth factor
independence and loss of contact inhibition compared
to normal CHO cells [12]. Implantation of Eag-trans-
fected cells in severe combined immune deficient mice
resulted in tumour formation. Eag expression has also
been detected by RT-PCR in cell lines from different
organs including as He-La (carcinoma of cervix),
SH_SY5Y (neuroblastoma) and various mammary cell
lines (COLO-824, EFM-19, BT_474). Inhibition of Eag
expression in EFM-19, HeLA, MCF-7, and SH-SY5Y
cell lines with antisense oligonucleotides reduced their
growth, demonstrating a role for Eag in cell prolifera-
tion [12]. Eag channel expression has also been demon-
strated in various clinical tumours [10] and cervical
cancer [13].
HERG (Human Ether-a-go-go related gene), also
belonging to the Eag family, plays a fundamental role in
cardiac excitability by regulating action potential repolar-
isation. It has been implicated in the molecular basis of
familial Long QT 2 syndrome [14]. A potential role of
these channels in cancer was first demonstrated in neu-
roblastoma cell lines [15] and they have since been
described in cells lines derived from a plethora of malig-
nant tissues and organs [16]. HERG expression has also
been demonstrated in clinical cancers that include endo-
metrial carcinoma [17], colorectal cancer [18] and acute
myeloid leukaemia [19]. HERG channels are important
determinants of the acquisition of an invasive phenotype
in colorectal cancers [18]. These studies indicate that
both Eag and HERG channels demonstrate the potential
to be used as tumour markers for ovarian cancer.
Further, specific blockers of these channels in conjunc-
tion with carboplatin, may be used as novel treatments in
order to reduce the dosage required for treatment and
associated side effects. They may also be considered as a
treatment for patients with resistant or recurrent disease.
This is the first study to examine the expression of
Eag and HERG channels in ovarian cancer biopsies,
with subsequent relation to prognostic factors. We also
sought to examine a role for Eag and HERG channels in
the proliferation of ovarian cancer cells.
Materials and methods
Cell culture
The SK-OV-3 cell line (Passage 13) was kindly donated
by Dimitra Dafou, Translational Research Laboratories,
University College Hospital, London in July 2008, from
an authenticated stock provided by the American Type
Culture Collection (ATCC). The cell line was cultured
in Dulbecco’s Modified Eagle’s Media (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and antibio-
tics (100 u/ml penicillin and 100 μg/ml streptomycin;
Invitrogen, Paisley, UK)
Antibodies
Rabbit anti-human Eag antibody was purchased from
Alomone Labs (Israel). Rabbit anti-human HERG anti-
body was from Abcam laboratories (UK) while second-
ary anti-rabbit fluorescein isothiocyanate (FITC)
conjugated antibodies were obtained from Sigma (Poole
UK). The antibodies were specific for the Eag and
HERG protein, as demonstrated by specific staining of
Eag and HERG protein in ovarian cancer tissue and
SKOV-3 cells on Western blotting (Figure 1).
Cell proliferation assay
The proliferation of SK-OV-3 cells was examined in the
presence and absence of voltage gated K+ channel block-
ers by (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt) MTS assay using the CellTiter 96 aqueous non-
radioactive cell proliferation assay kit (Promega, UK).
The assay was performed according to the manufac-
turer’s instructions to assess the effect of the voltage
gated K+ channel blockers, 4-aminopyridine (4-AP) and
tetraethylammonium (TEA) on proliferation of the
SK-OV-3 cell line. 5000 cells were added to each well of
a 96 well plate (Perkin Life Sciences) and incubated for
24 hours in 5% CO2/air at 37°C. Thereafter, the media
was aspirated and replaced with 100 μl fresh media
Figure 1 Western blot with samples from ovarian cancer tissue
and SK-OV-3 cells demonstrating specific staining for Eag and
HERG antibodies (Fig 1A and B) with corresponding actin blot.
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containing either 4-AP or TEA at various concentrations
or media only to serve as a control. The cells were incu-
bated for 96 hours and proliferation assessed daily by
the addition of MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt) reagent. Plates were then read at 490
nM using a Victor 1427 multilabel counter (Wallac). All
observations were performed in triplicate and experi-
ments repeated thrice.
Immunofluorescence
SK-OV-3 cells were grown on cover slips in 24 well plates
and incubated for 24 hours until 80% confluent. Cells
were then fixed with 4% paraformaldehyde for 20 min and
treated with 0.5% Igepal before blocking with 3% BSA/5%
glycine in PBS and 10% goat serum in PBS. Eag and
HERG (both 1: 50 and 1:100 in10% goat serum/PBS) anti-
bodies were added to the cover slips then incubated over-
night at 4°C. Wells containing 10% goat serum without
the primary antibody were used as a negative control.
After incubation, FITC conjugated secondary antibody at
1 in 50 dilution in 10% goat serum/PBS appropriate to Eag
and HERG was added and cells incubated at room tem-
perature for 90 min. Images of the cells were captured and
analysed using Cell F software (Olympus UK).
Immunohistochemistry
The ovarian cancer tissue microarray (TMA) (SDLREC
Ref 0205/495) was prepared from 336 patients who
underwent surgery for ovarian cancer from 1st January
1982 to 31st December 1998. Clinicopathological charac-
teristics recorded included age at diagnosis, Interna-
tional Federation of Gynecologists and Obstetricians
(FIGO) stage, grade, histological subtype, details of adju-
vant treatment, extent of cytoreduction and Disease
Specific Survival (DSS) which was then used for analysis.
DSS was calculated from the date of the operation until
31 Dec 2005, when any remaining survivors were
censored.
We calculated that a sample size of 336 patients
allowed an 80% chance of detecting a hazard ratio of
≥1.40 and ≤0.71 (N Query Advisor software). The TMA
were prepared by Ian Spendlove, University of Notting-
ham as described previously [20], and were kindly
donated to us. For each tumour, 5 μM section, slides
were stained with H&E to locate representative areas of
viable tissue. Needle core biopsies (0.6 mm) from the
corresponding areas on the paraffin embedded tumour
blocks were then placed in prespecified coordinates in
recipient paraffin array blocks using a manual tissue
arrayer (Beecher instruments). Five copies of the array
Figure 2 Immunocytochemistry of SK-OV-3 cells and effect of voltage gated K+ channel blockers 4-AP and TEA on their proliferation.
Immunofluorescence staining of SK-OV-3 cells with (A) Eag and (B) HERG antibodies. Eag localises to the cell membrane and cytoplasm with
little nuclear staining whereas HERG expression is mainly nuclear (higher magnification is shown in inset) (C) 4-AP significantly inhibited SK-OV-3
cell proliferation at 1,2 and 5 mM at 72 and 96 hrs while TEA (D) showed similar inhibition at 5 mM that was significant at 96 hours only.
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were assembled using different points within the repre-
sentative tumour area. 5 μM thick sections from each
TMA block were placed on coated glass slides to allow
for the procedure to be performed. Thus all the biopsies
in the TMA were representative of the sample and were
validated.
After dewaxing in xylene, tissue sections were rehy-
drated in a graded alcohol series and endogenous perox-
idase activity blocked by immersing the slides in 2%
hydrogen peroxide in PBS for 20 min. Antigen retrieval
was performed by microwaving the slides in 0.1 M
sodium citrate buffer at 800 W for 15 min followed by
400 W for 10 min. After blocking with horse serum, the
slides were incubated with either HERG antibody
(1:200) for 1 hour at room temperature or Eag antibody
(1:600) overnight at 4°C. Staining was developed using
the Vectastain Elite kit and di-aminobezidine (DAB)
chromagen (Dako, Hamburg, Germany) as per manufac-
turer’s instructions. Slides were counterstained with
Harris’s hamatoxylin and dehydrated in alcohol before
mounting in Depex for viewing.
The staining intensity was graded as: 0-no staining,
1-low, 2-intermediate and 3-high by three independent
observers (VA, HS and GVS) who had no knowledge of
the pathological variables or the disease outcome for the
dataset.
Statistical analysis
Analysis was performed using SPSS (version 17.0). Con-
tinuous data were analysed using median, interquartile
range (IQR) and 95% confidence intervals (CI). Fisher’s
exact tests were used for comparative analysis of catego-
rical data. Kaplan Meier survival estimates using log--
rank testing were determined for all baseline factors
specifically stage, grade, residual disease, adjuvant
chemotherapy, histological type, and Eag and HERG
immunostaining. In all cases, a P value of <0.05 was
considered statistically significant. The cell proliferation
assay data was analysed using one way analysis of var-
iance with Dunnett’s multiple comparison test (Graph-
pad Prism 5).
Results
1. Eag and HERG potassium channels are expressed in the
SK-OV-3 cell line
There is demarcated staining of the plasma membrane
of cells incubated with Eag antibody while nuclear stain-
ing was seen when the cells were incubated with HERG
antibody (n = 3; Figure 2A and 2B, higher magnification
is shown in inset). Diffuse staining of the cytoplasm and
nuclei was seen with both Eag (Figure 2A) and HERG
antibody (Figure 2B). No immunoreactivity was
observed in negative control experiments where primary
antibody was replaced with goat serum (Figure 2C).
2. K+ channel blockers inhibit cell proliferation of
SK-OV-3 cells
4-aminopyridine (4-AP) inhibited cell proliferation sig-
nificantly (P < 0.001) at concentrations of 1, 2 and 5
mM compared to control cells at 96 hours with
Table 1 Patient characteristics (n = 336)
Age at diagnosis, years, median (IQR) 62 (24-90)
Overall survival, months, median (IQR) 19.5 (0-271)
FIGO Stage n (%)
1 84 (25.0)
2 36 (10.7)
3 166 (49.4)
4 40 (11.9)
Missing 10 (3.0)
Grade n (%)
G1 39 (11.6)
G2 73 (21.7)
G3 221 (65.8)
Missing 3 (0.9)
Residual disease n (%)
No macroscopic disease (Optimal debulking) 128 (38.1)
Macroscopic disease left 194 (57.7)
Missing 14 (4.2)
Histological type n (%)
Serous 178 (53)
Mucinous 35 (10.4)
Endometriod 42 (12.5)
Clear cell 25 (7.4)
Undifferentiated 54 (16.1)
Missing 2 (0.6)
Chemotherapy n (%)
Yes 236 (70.2)
No 92 (27.4)
Missing 8 (2.4)
Eag staining n (%)
Low/Intermediate 196 (58.3)
High 53 (15.8)
Missing 87 (25.9)
HERG staining n (%)
Low/Intermediate 181 (53.9)
High 68 (20.2)
Missing 87 (25.9)
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maximum inhibition noted at 5 mM (n = 3). Tetraethy-
lammonium (TEA) inhibition of proliferating cells was
also noted at all concentrations at 96 hours (n = 3; P <
0.001) (Figure 2C and 2D) compared to untreated cells.
3. Eag is a significant prognostic marker for
ovarian cancer
Clinicopathological characteristics along with Eag and
HERG staining of 336 patients with ovarian cancer are
summarised in Table 1. The median age at diagnosis
and overall survival was 62 years (IQR 24-90) and
19.5 months (IQR 0-271) respectively. Nearly half of the
patients (49.4%) had FIGO stage 3 disease and two
thirds (65.8%) had grade 3 tumour. The predominant
histological type observed is serous (49.4%) followed by
endometriod (11.7%) and mucinous (9.7%). The intensity
of Eag and HERG staining was stratified into two groups
of high and low/intermediate staining (Figure 3A and
3B). The survival curves for these groups are shown in
Figure 3C and 3D. Biopsies with an insufficient number
of cancer cells to produce a reliable result were not
included in the final analysis. Patients with high Eag
staining had significantly poor survival of 13.8 months
(CI 7.2-20.3) compared with 24.1 months (18.9-29.2);
(P = 0.016) for the low/intermediate group (Table 2).
HERG staining did not show significant correlation with
survival (P = 0.586). Other prognostic markers for ovar-
ian cancer such as stage, grade, residual disease, histolo-
gical type and adjuvant therapy also showed significant
differences in median survival (Table 2).
Following identification of a significant association of Eag
staining with survival, further evaluation was carried out
between the two groups of patients with Eag staining and
other prognostic makers. There was no difference in the
proportion of patients with stage of disease (P = 0.587), his-
tological type (P = 0.622) or receiving adjuvant chemother-
apy (P = 0.594), but there was significant correlation
between high Eag staining, grade of tumour (P = 0.014)
and residual disease left after the operation (P = 0.011)
(Table 3). On Cox multivariate analysis (Table 4) patients
with high Eag staining did not show a significant effect (P
= 0.215) on overall survival compared to other prognostic
markers like FIGO stage and residual disease. Staining of
normal ovary (n = 6) demonstrated low level expression of
both Eag and HERG on the surface epithelium compared
to ovarian cancer (shown by arrow in Figure 3C).
Figure 3 Immunohistochemical staining of ovarian cancer tissues and normal ovary and its correlation with survival. Representative
section from a tissue microarray set showing (A) high and (B) low Eag immunohistochemical expression and low staining on the surface
epithelium (arrow) of normal ovary (C). Similar results were obtained for HERG. (D) Kaplan-Meier survival curves from data represented on the
above TMA show high Eag expression is associated with poor prognosis (P = 0.016), whereas increased HERG expression (E) is not.
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Discussion
Voltage gated K+ channels have been implicated in cell
proliferation and the control of cell cycle progression.
They also show cell and tissue-specific expression, and
impaired expression of K+ channels has been detected
in a number of cancer and tumour cells [21].
Both K+ channel blockers, 4-AP and TEA, significantly
inhibited the proliferation of Eag and HERG-positive
SK-OV-3 cells, confirming data by Zhanping et al., on
the A2780 ovarian cancer line [5]. Both TEA and 4-AP
are non selective K+ channel blockers capable of inhibit-
ing Eag and HERG as well as other voltage gated K+
channels. The therapeutic potential of blocking Eag and
HERG channels non-specifically may be limited by cardi-
otoxicity toxicity resulting from impaired HERG channel
activity in the heart. However, recently a monoclonal Eag
antibody has been developed which specifically inhibits
proliferation based on its Eag blockade with no interac-
tion with HERG channels and has been postulated as a
potential therapeutic for the treatment of cancer [22].
We show here that high Eag expression is associated
with poor prognosis in patients with ovarian cancer.
Hemmerlein et al., have reported the presence of Eag
channels in ovarian cancer tissue but no expression with
normal ovarian follicular epithelium [10].
High Eag expression is also associated with high grade
ovarian cancers and the presence of residual disease at
Table 2 Median survival based on Eag and HERG
immunoreactivity and other prognostic markers
Median survival,
Months(IQR)
P (log
rank)
Eag staining
Low/Intermediate 24.1 (18.9-29.2)
High 13.8 (7.2-20.3) 0.016
HERG staining
Low/Intermediate 22.4 (14.1-30.6)
High 16.4 (9.7-23.0) 0.586
Stage
1 137.6 (48.8-226.3)
2 28.4 (4.8-51.9)
3 13.0 (9.0-16.9)
4 7.3 (0-15.2) < 0.001
Grade
G1 28.9 (17.2-40.5)
G2 33.1 (16.4-49.7)
G3 16.0 (13.0-18.9) 0.001
Residual disease
No macroscopic disease (Optimal
debulking)
65.2 (37.5-92.8)
Macroscopic disease 10.7 (7.6-13.7) < 0.001
Histological type
Serous 17.3 (12.6-21.9)
Mucinous 30.7 (0-64.7) < 0.001
Endometriod 26.6 (5.3-47.8)
Clear cell 155 (89.7-222)
Undifferentiated 13.3(5.3-21.2)
Adjuvant
Chemotherapy
Yes 20.3 (15.4-25.1)
No 18.8 (0.6-36.9) 0.04
Table 3 Distribution of prognostic markers for ovarian
cancer stratified by Eag staining (Fisher’s exact test)
Prognostic Markers No of patients
stratified by Eag
staining
P
value
Low/
Intermediate
High
Stage
1 52 10 0.587
2 23 7
3 92 30
4 23 5
Grade
G1 19 13 0.014
G2 44 7
G3 133 32
Residual disease
No Macroscopic disease (Optimal
debulking)
85 13 0.011
Macroscopic disease 102 38
Histological type
Serous 110 27 0.622
Mucinous 17 8
Endometriod 24 6
Clear cell 17 3
Undifferentiated 28 9
Adjuvant Chemotherapy
Yes 144 37 0.594
No 48 15
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surgery, which in turn is associated with poor outcome,
but no correlation between tumour stage, histological
type or adjuvant chemotherapy was demonstrated. In
contrast to our findings, no association has been shown
between Eag expression and different grades of tumour
in soft tissue sarcoma patients [23] which may be due to
the non epithelial origin of these tumours. Eag channels
are expressed on the surface of the cell membrane are
attractive targets for novel treatments in management of
ovarian cancer. HERG expression did not show any dif-
ference in survival indicating that HERG channels as
targets may not have a therapeutic role in ovarian can-
cer. Though both Eag and HERG channels belong to
the same Eag family and despite blockade by the voltage
gated blockers and similar positivity on staining, these
two channels give rise to very different electrical cur-
rents and have different functional role in human tis-
sues. This difference in functionality may be one of the
reasons that Eag is linked to poor survival while HERG
is not. This is likely to be mediated through cellular
mechanisms that link to changes in membrane potential
which we intend to explore further. Eag showed signifi-
cant survival difference on univariate analysis, but there
was no significant difference on Cox regression analysis
which may be due to insufficient number of patients
and having a larger cohort may also change the differ-
ence between the two markers.
Conclusion
In summary, we have demonstrated for the first time
that Eag and HERG K+ channels are overexpressed in
ovarian cancer and that high Eag staining is associated
with significantly poorer survival, identifying Eag as a
putative prognostic marker. Moreover inhibiting prolif-
eration of ovarian cancer cells using K+ channel blockers
indicates that they have a role in ovarian cancer cell
proliferation. Further research into specific Eag blockers
or using RNA interference to silence the Eag gene is
required in order to elucidate the role of Eag channels
in ovarian cancer progression and their link to clinical
outcome.
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